LUCDHealthcare · Medical DevicesThe 5 Wall Street analysts covering Lucid Diagnostics, Inc. hold a median 12-month price target of $3 — +638.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lucid Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LUCD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +638.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | BTIG | Reiterates | Buy | $2.50 |
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | $9.25 → $9.50 |
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | — |
| 17 Aug 2026 | BTIG | Reiterates | Buy | — |
| 17 Aug 2026 | BTIG | Reiterates | Buy | $2.50 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $9.00 → $9.25 |
| 15 May 2026 | BTIG | Reiterates | Buy | — |
| 15 May 2026 | Maxim Group | Maintains | Buy | — |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 30 Mar 2026 | BTIG | Reiterates | Buy | — |
| 26 Mar 2026 | Needham | Reiterates | Buy | — |
| 10 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 13 Nov 2025 | Needham | Reiterates | Buy | — |
| 6 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 10 Sept 2025 | BTIG | Reiterates | Buy | — |
| 5 Sept 2025 | BTIG | Maintains | Buy | — |
| 13 Aug 2025 | Needham | Reiterates | Buy | — |
| 16 July 2025 | Needham | Reiterates | Buy | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LUCD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Lucid Diagnostics, Inc. returned −66.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 10% of US stocks
Cheaper than 13% of US stocks
Cheaper than 71% of US stocks
Higher than 76% of US stocks
Higher than 64% of US stocks
Higher than 5% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 3% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lucid Diagnostics, Inc. has a market value of $77.3M and an enterprise value of $67.7M.
Revenue in the twelve months to 30 June 2026: $5.4M. The latest quarter grew 26.7% year on year.
Net income over the same four quarters: −$52.3M, a −959.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.45.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Trailing P/E: −0.9×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lucid Diagnostics, Inc. employs 82 people — $66K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lucid Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PAVmed announced it will hold a third-quarter 2026 business update conference call and webcast on November 13, 2026, at 8:30 a.m. ET.
Why it matters — The announcement concerns PAVmed, which operates in diagnostics among other sectors, and may be of interest to LUCD watchers following the diagnostics space.
Lucid Diagnostics announced it will hold a business update conference call and webcast on November 12, 2026, at 8:30 a.m. ET. CEO Lishan Aklog, M.D., will participate.
Why it matters — The event gives LUCD watchers a scheduled opportunity to hear a business update from the company.
Lucid Diagnostics said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test at the established Clinical Laboratory Fee Schedule rate. The company also closed a $15 million private placement of Series C Convertible Preferred Stock with existing long-term shareholders.
Why it matters — The Medicare payments and financing affect Lucid’s reimbursement activity and balance sheet, with proceeds intended to support its cash runway and near-term commercial acceleration.
Lucid Diagnostics announced advances in payment, billing, and coding pathways for its EsoGuard and EsoCheck products, following three public meetings. These include a Medicare Advisory Panel recommendation to maintain EsoGuard's gapfill payment basis, AMA CPT approval of a new Category III code for EsoCheck procedures, and a favorable response to a proposed new ICD-10-CM diagnosis code for positive EsoGuard results.
Why it matters — These coding, billing, and payment advances could strengthen reimbursement coverage and market accessibility for Lucid's EsoGuard and EsoCheck products.
Lucid Diagnostics is positioning its EsoGuard test as a non-invasive tool for identifying Barrett's Esophagus while awaiting a Medicare coverage decision and expanding relationships with commercial payers, the Department of Veterans Affairs, and health systems.
Why it matters — The Medicare coverage decision and expanding payer and health system relationships could significantly determine EsoGuard's adoption and revenue potential.
The 5 Wall Street analysts covering Lucid Diagnostics, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $9.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Lucid Diagnostics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lucid Diagnostics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Lucid Diagnostics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +638.2% from the last close, and Ticker Nerd's factor model ranks Lucid Diagnostics, Inc. 36 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lucid Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUCD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $9.5 over the next 12 months.
Lucid Diagnostics, Inc. returned -66.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD.
The most recent item we track (PRNewsWire, 30 Oct 2026): "PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026". PAVmed announced it will hold a third-quarter 2026 business update conference call and webcast on November 13, 2026, at 8:30 a.m. ET.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.
CEO Dr. Lishan Aklog M.D. · 82 employees · United States · https://www.luciddx.com
